← Drug database

Armisarte (previously Pemetrexed Actavis) (pemetrexed)

Region
🇪🇺 EU
Active substance
pemetrexed
Company
Actavis Group PTC ehf
Status
Authorised
Therapeutic area
Carcinoma, Non-Small-Cell Lung; Mesothelioma
CHMP opinion
Thu 19 Nov 2015
EU approval
Mon 18 Jan 2016
Application
EMEA/H/C/004109
ATC
L01BA04
Official record
www.ema.europa.eu

Indication

Malignant pleural mesothelioma Pemetrexed in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non-small cell lung cancer Pemetrexed in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. Pemetrexed is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Armisarte (previously Pemetrexed Actavis)

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.